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INTRODUCTION 
1.1- History of herbal medicine 
  India is the largest producer of medicinal herbs and is rightly called the 
“Botonical garden of the world”. There are very few plants of commercial 
importance, which are not collected or cultivated in this country. Medicinal plants 
have been in use for thousands of years, in one form or the other, under the 
indigenous systems of medicine like Ayurveda, Siddha and Unani. Since 
Independence in 1947, India has made tremendous progress in agrotechnology, 
process technology, standardization, quality control, research and development etc. 
Research and Development is an integral part of any industry and herbal drug industry 
is no exception. Guggulipid, Neem products, Vincristine, Vinblastine, Sennosides, 
Psyllium husk, Reserpine and many others have achieved international recognition. 
India is one of the world’s 12 leading biodiversity centers with the presence of over 
45,000 different plant species.  Not so many years ago the advances being made 
in medicine and the innovation of the pharmaceutical industry made it seem inevitable 
that the use of herbal remedies in developed countries would decline to insignificance. 
In the early 19th century, when methods of chemical analysis first became available, 
scientists began extracting and modifying the active ingredients from plants. Later, 
chemists began making their own version of plant compounds, beginning the 
transition from raw herbs to synthetic pharmaceuticals. Over time, the use of herbal 
medicines declined in favor of pharmaceuticals. It is somewhat of a paradox, 
therefore, that at a time when there is an unprecedented number of therapeutic drugs 
available for the treatment of all forms of disease that herbal medicines continue to be 
demanded by the general public, which has been steadily increased over the past 
decade . Millions of the people in the third world opt for herbal medicines because 
they believe in them. They also regard them as their system of medicine. It has often 
been stated that people prefer herbal medicines because it is cheaper. About 80% 
of4000 million inhabitants of the world rely on herbal medicines for their first kind 
ofhealth care because they cannot afford allopathic medicines. This may not be a 
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correct assessment of actual situation. Many of those persons using herbal medicines 
would continue to use these even if the prices of allopathic medicines come down. 
Many people in Europe, the United Kingdom and the United States of America are 
turning to alternative medicine because of the side effects induced by powerful 
synthetic allopathic drugs. Several of the very important useful medicines we use 
today come from plants. Many of these have now been synthesized and the synthetic 
drugs are used. In other instances it is easier to obtain from plants even if these can be 
synthesized. Some of these medicines are ephedrine, morphine, quinine, emetine, 
reseipine, digitalis, ergot and vincristine. Herbal medicine, also called botanical 
medicine or phytomedicine, refers to the use of any plant's seeds, berries, roots, 
leaves, bark, or flowers for medicinal purposes. Long practiced outside of 
conventional medicine, herbal therapy is becoming more focussed as up-to-date 
analysis and research show their value in the treatment and prevention ofdisease.  
1.2. Herbal Medicine Usage 
   For most herbs, the specific ingredient that causes a therapeutic effect is not 
known. Whole herbs contain many ingredients, and it is likely that they work together 
to produce the desired medicinal effect. For these reasons, people prefer using whole 
plants rather than extracting single components from them. Whole plant extracts have 
many components. These components work together to produce therapeutic effects 
and also lessen the chances of side effects from any one component. Several herbs are 
often used together to enhance effectiveness and synergistic actions and to reduce 
toxicity. The treatment goals are often more broad than stopping a single complaint. 
Herbal therapy aims to correct imbalances, resolve patterns of dysfunction, and treat 
the underlying cause of complaint. Specific symptoms may also be treated if 
necessary. It also recommends one or more herbs, dietary changes, and lifestyle 
modifications. Herbal medicines are slower acting than pharmaceuticals. Herbal 
dosage is a difficult concept to grasp; partly, this is because of the limitations in our 
knowledge about the herbs, but it is also the result of variations in our concepts of 
how herbs may contribute to health. For example, we have our own limitations 
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because we often do not know the identity of the main active constituents or their 
quantities, nor how those quantities might vary among samples of the raw materials, 
or how they might be affected by the way the herbs are prepared. As to conceptual 
framework, some people think of herb action in terms of "energetics" in which the 
quantity of the herb might not be critical; this is an unorthodox idea, one, which has 
influenced western practitioners via homeopathy. By contrast, many people would 
think of herbs in terms of the pharmacological effects of the main active ingredients, 
in which case a certain dosage range will yield those effects, but lower doses may fail 
to give the desired results; this is a modem scientific viewpoint. In fact, many people 
don't give much thought to the question of dosage. An added complication is that both 
the traditional and modem methods of preparation of herbs are sometimes selected on 
the basis of what is technologically feasible, what is convenient, dr what is affordable, 
rather than what might be ideal from the consideration of traditional practices or 
clinical efficacy. Decoctions, dried decoctions, powders, dried extracts, tinctures, and 
pills are some of the dosage forms ofherbs.  
1.3. Conventional drug use  
 Although superficially similar, herbal medicine and conventional 
pharmacotherapy have three important differences: > Use of whole plants: People 
generally use unpurified plant extracts containing several different constituents. They 
claim that these can work together synergistically so that the effect of the whole herb 
is greater than the summed effects of its components. They also claim that toxicity is 
reduced when whole herbs are used instead of isolated active ingredients 
("buffering"). Although two samples of a particular herbal drug may contain 
constituent compounds in different proportions, practitioners claim that this does not 
generally cause clinical problems. There is some experimental evidence for synergy 
and buffering in certain whole plant preparations, but how far this is general sable to 
all herbal products is not known. > Herb combining-. Often, several different herbs 
are used together. Practitioners say that the principles of synergy and buffering apply 
to combinations of plants and claim that combining herbs improves efficacy and 
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reduces adverse effects. This contrasts with conventional practice, where 
polypharmacy is generally avoided whenever possible. > Diagnosis: Herbal 
practitioners use different diagnostic principles from conventional practitioners. For 
example, when treating arthritis, they might observe, "under functioning of a patient's 
systems of elimination" and decide that the arthritis results from "an accumulation of 
metabolic waste products." A diuretic, choleretic, or laxative combination of herbs 
might then be prescribed alongside herbs with anti-inflammatory , properties. 44 > 
Polyvalency: Many herbs contain a wide range of active ingredients, which act in a 
variety of ways rather than just at one receptor — the concept of herbal polyvalency. 
A good example would be mistletoe (Viscum album), which is one ofthe most widely, 
used oncological treatments in Germany. Its various active ingredients prevent 
DNA/RNA synthesis; stimulate the production of natural T killer cells and cytokines 
such as interleukins 1 and 6 and TNF-a. It works with the body’s immune system 
rather than against it.  
1.4. Some Advantages of Herbal Remedies 
  Herbal remedies cost less than medicines, and are certainly much more 
convenient One of the good things about herbals and dietary supplements is that the 
patient is empowered. One advantage is wide availability and simple preparation. One 
can purchase herbal supplements even without a prescription. Most herbs can be 
prepared with means we all have access to, such as making teas, extracting with 
alcohol, or similar. This is a large factor in cost of treatment. Herbs are also very well 
researched. If we pool the knowledge from diverse traditions, we have a cure for just 
about every illness known to man. Moreover herbs have been around in nature for 
millennia mid our bodies are - one way or another accustomed to their presence. 
Pharmaceutical medicines on the other hand often introduce a completely new 
molecule that has never before been present, and it is difficult to predict (or find out 
without widespread use) what the exact effects are. The FDA regulates medicines, 
which are one of the most UNSAFE product categories in existence, to where they 
have become a major cause of concern. Herbs, on the other hand, are ultra-safe by 
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comparison. Herbal medicine has a better future. The importance of traditional system 
of medicine and of certain traditional medical practices has now been recognized all 
over the world. Among the various systems of traditional medicines, Ayurveda stand 
out distinctly as not only a system of great antiquity but an organized system with 
distinct aims and objectives. According to the World Health Organisation, herbal 
(traditional) medicine is used by 80 % of Africans and large sections ofthe world 
population rely on it as their primary form of health care. Up to 25% of all 
prescriptions in Europe and America, contain plant products, which were originally 
derived from plants. Pharmaceutical medicine is either going to be deeply reformed or 
it will die. Once awareness spreads of the amount of damage being done in the name 
of pharmaceutical medicine, there will be a widespread move away from it towards 
more gentle and safer forms of medical care. Bad experiences with herbal medicine 
seem to be extremely rare by comparison. Herbal remedies are infinitely safer than 
allopathic medicines. There is really no comparison in seriousness and number of 
cases ofside effects. There are several disorders, wherein allopathic treatment results 
in serious side effects. Moreover some of the disorders like anxiety, hypertension, and 
depression are not completely cured by allopathic therapy. Many still rely on 
indigenous formulation. 
1.5. Anxiety 
  Anxiety is a normal emotion when it is appropriate to the environmental 
situation. Inappropriate or pathological anxiety is a well-recognized and common 
condition, which causes considerable distress to individuals, families and society in 
general. Anxiety disorders present in a number of forms, although, probably, all share 
a number of common neurological circuits. While certain psychological treatments 
are of proven efficacy of pharmacotherapy have remains the most widespread and 
efficacious treatment, especially in severe cases. Anxiety has evolved biologically as 
a functional state and, therefore, is both normal and pathological. Furthermore, it can 
be both a symptom of a wider psychiatric disorder and the primary disturbance in a 
group of similar, but distinguishable, illnesses, the 'anxiety disorders. 
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 Normal anxiety has evolved as a way of controlling an animal's response to 
threatening or potentially threatening stimuli. This is not just through the classic three 
‘canonical’ options of fight, flight, or freeze, but also through approach avoidance, 
anticipatory fear, and the generally increased levels of arousal and performance that 
accompany high normal levels of anxiety. The concept of a graded progression from 
functionally useful arousal through to disruptive and maladaptive anxiety has appeal, 
and it could be argued that pathological anxiety is essentially a maladaptive level of 
arousal. Unfortunately, there is increasing evidence that what we broadly call anxiety, 
from a neurobiological viewpoint, may not be a unitary concept Anxiety varies not 
just in time and intensity, but also in quality. Free-floating worry is somewhat 
different from the fearful anticipation of unwanted challenges, which is similarly 
different from the intense, short lived, unpredictable, and irrational paroxysm of a 
panic attack. These are normal responses under the appropriate conditions, but 
pathological and maladaptive if incongruent to the situation. These phenomenological 
differences to some extent are backed up by differences in physiological changes, 
biological markers, and pharmacological response  and have led psychiatrists to a 
more detailed way to describe and operationalise the individual symptoms of anxiety. 
This has led to a classification of anxiety disorders based on symptom patterns. 
Taking into account the phenomenology (intensity, length, quality, and natural history 
of anxiety symptoms), along with differences in biology (genetics, physiological 
markers, and  pharmacological responses), psychiatrists have constructed syndromes 
that now constitute a widely accepted typology. Both the DSM-IV (Diagnostic and 
statistical manual of mental disorders-IV edition)(American Psychiatric Association,  
and the ICD-10 (International classification of diseases-10th revision) (World Health 
Organization, 1992) have similar subgroups (Table ). 
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Table 1. Classification of anxiety disorders 
Clinical Condition State of Disease / Disorder 
Panic disorder with agoraphobia Agoraphobia with panic disorder 
Panic disorder without agoraphobia Panic disorder 
DSM-IV (American Psychiatric 
Association)/ anxiety disorders 
ICD-10 (World Health Organization)/ 
neurotic stress, and somatoform 
disorders 
Agoraphobia Agoraphobia without panic disorder 
Specific phobia Specific phobia 
Social phobia (also known as social anxiety 
disorder) 
Social phobia 
Generalized anxiety disorder-GAD Generalized anxiety disorder Mixed 
anxiety and depression disorder 
Obsessive compulsive disorder-OCD Obsessive compulsive disorder 
Acute stress disorder Acute stress disorder 
Post traumatic stress disorder-PTSD PTSD Adjustment disorder 
 
1.6. Mechanism of actions of some Herb 
 The plant extracts and isolated bacosides have been extensively investigated 
for their neuropharmacological effects. The triterpenoid saponins and their bacosides 
are responsible for plants ability to enhance nerve impulse transmission. It was 
suggested that bacosides induce membrane dephosphorylation, with a concomitant 
increase in protein and RNA turnover in specific brain areas. The other proposal that 
was put forward was that plant enhances protein kinase activity in the hippocampus 
which may also contribute to its nootropic action and thus it would aids in repair of 
damaged neurons by enhancing kinase activity, neuronal synthesis, and restoration of 
synaptic activity and ultimately nerve impulse transmission. 
Earlier studies reported a sedative effect of glycosides named hersaponins. 
Subsequent study has found that the alcoholic extract, and to a lesser extent the 
aqueous extract of the whole plant exhibited tranquilizing effects on albino rats and 
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dogs. On the other hand, it has been found that the alcoholic extract of the plant and 
chlorpromazine improved the performance of rats in motor learning. A previous study 
has reported that a single dose of the glycoside hersaponin is better than 
pentobarbitone in facilitating acquisition and retention of brightness discrimination 
reaction. 
 Research using a rat model of clinical anxiety demonstrated that a BME 
containing 25- percent bacoside A exerted anxiolytic activity comparable to 
lorazepam, a common benzodiazepine anxiolytic drug and it was noted with attention 
that the BME did not induce amnesia, the side effects associated with lorazepam, but 
instead had a memoryenhancing effect. The antidepressant potential of BM has been 
evaluated in an earlier study wherein it showed a significant antidepressant activity in 
the most commonly used behaviour paradigms in animal models of depression, 
namely, forced swim test and learned helplessness test. In the study, the BME in the 
doses of 20 to 40 mg per kg was given once daily for five days and were found to be 
comparable to that of standard antidepressant drug imipramine in rodents for 
antidepressant activity. The same study has postulated the role of serotonin and 
GABA (gamma amino butyric acid) as the mechanism of action attributed for its 
antidepressant action along with its anxiolytic potential, based on the compelling 
evidence that the symptoms of anxiety and depression overlap each other.  
1.7. Neuroanatomy of anxiety  
 The potential role of 5-hydroxytryptamine (5-HT) in anxiety has been the 
subject of an impressive amount of investigation, most of it addressed to the 
hypothesis that 5-HT promotes anxiety and, therefore, drugs that reduce 5-HT 
function will be effective anxiolytic agents in human anxiety disorders. Yet, results 
are beginning to accumulate that a group of drugs 48 that increase 5-HT function, the 
selective serotonin reuptake inhibitors (SSRIs), are actually effective in anxiety 
disorders, with a broader spectrum of action than the benzodiazepines. What does this 
mean for theories of 5-HT function in anxiety? There have been recent developments 
in understanding the neurobiology of mammalian responses to threatening stimuli. 
There is also increasing understanding of the characteristics of 5-HT neurons-what 
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their firing patterns are, what receptor subtypes are involved and how 5-HT 
transmission is controlled. New and powerful tools, such as in- vivo dialysis in the 
behaving animal, studies on knock out - animals (genetically mutated animals with 
specific genes inactivated) and radiolabelled techniques have been introduced.  
1.8. Anxiety models in animals  
 Anxiety is a common emotion in humans and can be expressed with words. 
We do not know animals’ words but can understand that they have a variety of 
feelings, including anxiety, by observing their behaviour. Attempts have been made to 
analyse anxiety by observing animal’s behaviour in an artificial environment, which 
were classified into two different types: with the use or without the use of 
punishment. Geller and Seifter experimentally created a conflict state in rats by using 
food pellets (positive reinforcer) and electrical foot shock (punishment). Through 
lever pressing hungry rats were trained to take food pellets with and without an 
electric foot shock. The rats’ distress state to press or not to press the lever caused by 
fear of punishment is thought to be similar to conflict state in humans, i.e., anxiety. 
Clinically effective anxiolytics suppressed the conflict state in rats, causing them to 
press the lever more frequently inspite of an electric shock and also created a similar 
conflict state in thirsty rats by using two different stimuli, water and electric shock. 
With their methods rodents were motivated by restraint of physiological desire, 
namely food or water deprivation, to want the positive reinforcement. Similar 
methods measuring anxiety based on punished behaviour have been performed in 
other animals such as pigeons and monkeys. Another approach to analyse anxiety in 
rodents is based on exploratory behaviour by creating a conflict between their 
aversion to special environment and their desire for exploration without food or water 
deprivation. Different models of anxiety are classified given below:   
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1.8.1. Unconditioned Behaviour 
 A. Exploratory behaviour 
 i. Elevated plus maze  
ii. Zero maze test  
iii. Open field test 
 iv. Staircase test 
 v. Hole board test  
vi. Light- dark exploration  
vii. Latency to enter mirrored chamber test  
B. Social Interaction test  
C. Conflict models 
 i. Geller -Seifter test  
ii. Vogel’s test iii.  
Four - plate test  
D. Miscellaneous tests:  
i. Novelty induced suppression of feeding and drinking 
ii. Defensive burying test 
 iii. Cork-gnawing test 
 iv. Defeat-induced analgesia  
  v. Ultrasonic pup vocalization  
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  vi. Foot shock induced ‘freeze’ test 
  vii. Anti aggression test  
 viii. Anti stress test  
ix. Drug withdrawl-induced anxiety Proconvulsant and anticonvulsant activity. 
1.8.2. Conditioned Behaviour 
 i. Passive avoidance  
ii. Active avoidance  
iii. Conditioned emotional response 
 iv. Conditioned place preference  
 v. Conditioned defensive burying 
 vi. Suppression of discriminative learning 
 vii. Conditioned taste aversion  
viii. Drug discrimination. 
1.9. Clinical studies  
1.9.1. Cognition  
 Numerous clinical studies have been carried out to date, to establish the 
efficacy of plant in memory and attention disorders and to study its acute and chronic 
effects clinically on cognitive function. A study was conducted to measure the effect 
of plants on human memory.  In seventy six adult volunteers, aged between 40 and 65 
years in double-blind randomized placebo control study, the results showed a 
significant effect of plant on the test for the retention of new information. In the 
follow-up tests it was found that the rate of learning was unaffected, suggesting that 
BM decreases the rate of forgetting of newly acquired information. In adults, only 
chronic administration was shown to enhance cognitive effects. In a double-blind, 
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placebo-controlled trial of 38 healthy volunteers (ages 18-60), subjects were given a 
single dose (standardized to 55-percent combined bacosides A and B) or placebo. As 
demonstrated in a double-blind, placebo-controlled, 12-week trial which utilized the 
same patient selection criteria and same dose of plant containing 55-percent combined 
bacosides. Forty-six healthy volunteers (ages 18-60) were randomly and evenly 
divided into treatment and placebo groups. The same series of tests administered in 
the acute dosage trial were administered at baseline, five, and 12 weeks after 
treatment began. At the end of the 12- week study, results indicated a significant 
improvement in verbal learning, memory consolidation, and speed of early 
information processing in the treatment group compared to placebo. These effects 
were not observed at baseline or at five weeks. These results were attributed to BM’s 
antioxidant properties and/or its effect on the cholinergic system. BM’s ability to 
modulate or enhance cognitive function has also been studied in children. In one 
double-blind, placebo-controlled randomized study, the efficacy of standardized 
plants in subjects with age-associated memory impairment (AAMI) without any 
evidence of dementia or psychiatric disorder was evaluated. plant was found to be 
efficacious in subjects with age-associated memory impairment . Anxiety and 
depression The traditional use of plant as an anti-anxiety remedy in Ayurvedic 
medicine is supported by both animal and clinical research. A one-month, limited 
clinical trial of 35 patients with diagnosed anxiety neurosis demonstrated that 
administration of brahmi 38 syrup (30 mL daily in two divided doses, equivalent to 12 
g dry crude extract of above plant resulted in a significant decrease in anxiety 
symptoms, level of anxiety, level of disability, and mental fatigue, and an increase in 
immediate memory span. Other changes noted were increased body weight, decreased 
respiration rate, and decreased systolic blood pressure. In one latest study, effects of 
some dose on cognitive performance, anxiety, and depression in the elderly were 
evaluated in a randomized, double-blind, placebo-controlled clinical trial with a 
placebo run-in of 6 weeks and a treatment period of 12 weeks. In fifty-four 
participants aged 65 or older (mean 73.5 years), without clinical signs of dementia, 
were recruited and randomized to plant or placebo. Forty-eight (48) completed the 
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study with 24 in each group. BM participants were found to have enhanced Auditory 
Verbal Learning Test (AVLT), delayed word recall memory scores relative to 
placebo, decreased Center for Epidemiologic Studies Depression scale (CESD-10) 
depression scores, combined state plus trait anxiety scores, and heart rate over time 
compared to that of placebo group. In India, the Ayurvedic doctors use it without any 
ill effects in children, pregnant ladies and breast feeding mothers but no parallel 
studies of its use in children, pregnant and breast feeding women regarding toxicity or 
herb-drug interactions, unlike modern pharmacological drugs are available, so its use 
may warrant precautions. 
 
1.9.2. Benzodiazepines 
  Unfavourable side effect profiles of MAOIs, TCAs & barbiturates, the 
discovery of the benzodiazepines (BZs) in 1950s was to revolutionize the treatment of 
anxiety. In addition to their anxiolytic properties, BZs also possess sedative, hypnotic, 
anticonvulsant and muscle relaxant actions & the sedative & muscle relaxant 
component of BZs activity may augment the anxiolytic effect. At present, a number of 
drugs with various mechanisms of action are available for the pharmacotherapy of 
anxiety. 
 In the light of the unfavorable side-effect profiles of barbiturates, MAOIs and 
TCAs, the discovery of the benzodiazepines (BZs) in the 1950s was to revolutionize 
the treatment of anxiety. In 1960 the first member of this class to be marketed was 
Librium (Chlordiazepoxide) and for the next 40 years benzodiazepines were the 
mainstay of anxiety treatment. In addition to their anxiolytic properties, 
benzodiazepines also posses sedative, hypnotic, anticonvulsant and muscle relaxant 
actions and the sedative and muscle relaxant component of benzodiazepine activity 
may augment the anxiolytic effect. This overlap of pharmacodynamic activities blurs 
the distinction between sedatives and true anxiolytics and the classification of a 
benzodiazepine as an anxiolytic is based heavily on pharmacokinetic considerations, 
with long and short-lived benzodiazepines being used as anxiolytics and hypnotics, 
respectively. Over the last 40 years the benzodiazepines are still extremely popular.  
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In clinical practice60 BZs are widely used for GAD and as prophylactics in situational 
anxiety, with Diazepam historically being the most popular choice. Others in common 
use are Chlordiazepoxide, Clorazepate, Lorazepam, Alprazolam, Oxazepam, 
Bromazepam and Clonazep. 
 Buspirone is a member of the azapirone class  and produces its therapeutic 
effects through partial agonism at 5HT-1A receptors. Buspirone is indicated and 
widely used for GAD, but has failed to show significant efficacy in other anxiety 
disorders. Although perhaps less consistently effective than the BZs, Buspirone’s 
improved safety profile provides the main point of differentiation between the two 
therapies. Buspirone cause less sedation, motor and cognitive impairment and does 
not appear to be associated with any withdrawal syndrome. Drawbacks include a 
delayed onset of action (several weeks) and a reduced effect in patients who have 
recently used benzodiazepines.64 Buspirone is the only member of the azapirone class 
to be marketed in the US, although tandospirone65 is registered in Japan. 
Paroxetin is the most widely used SSRI in the treatment of anxiety and is approved 
for OCD and panic disorder and is currently the only SSRI indicated for social phobia 
and GAD. Fluvoxamine73 is the first SSRI to gain approval for OCD. Fluoxetine74 
and Sertraline75, 76 are also indicated for OCD. Now it is also approved for panic 
disorder and recently became the first and only mediation approved for PTSD. In the 
US, Citalopram77 is indicated for use in OCD and has been used to prevent panic 
attacks for several years in Europe. Venlafaxine is a dual serotonin and 
norepinephrine reuptake inhibitor (SNRI) that has been approved for used in 
GAD.78,79 The major drawback of the SSRIs in comparison to the Bas is their 
delayed onset of action. As with their antidepressant effect, it takes 2-4 weeks. 
 
1.10. Adverse Effects 
  The MAOIs are associated with a number of undesirable side effects including 
weight gain, postural hypotension, sexual dysfunction and insomnia. The most serious 
side effect is the risk of tyramine-related hypertensive crisis, often referred to as the 
“cheese effect” which can be fatal. To avoid this situation patient taking MAOIs must 
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limit their tyramine intake and the restrictive diet required to accomplish this leads to 
low patient compliance. The therapeutic effects of the TCAs derive from their 
inhibition of serotonin and norepinephrine uptake, although they also act at 
muscarinic acetylcholine receptors, histamine H1 receptors and α1-adrenergic 
receptors. Common anticholinergic side effects include dry mouth, constipation, 
urinary retention and blurred vision. Blockade of adrenergic receptors can cause 
orthostatic hypotension and dizziness and actions at histamine receptors leads to 
sedation and weight gain.  
  TCAs have largely relegated these drugs to last resort cases where other 
medications have failed. The benzodiazepines have demonstrated a remarkable safety 
profile and their high tolerability has been a major factor in their widespread 
acceptance and phenomenal success. The most commonly reported side effects with 
benzodiazepine anxiolytics are daytime sedation (‘hangover’ effect), sleep 
disturbances, cognitive impairment, motor in coordination and ataxia. The latter 
symptoms are of greater importance in the elderly in whom they are associated with 
an increased incidence of falls and fractures.80 The greatest problems with the 
benzodiazepines are withdrawal symptoms, dependency liability and abuse potential, 
the separation of which is not always obvious. 
  Abrupt discontinuation of benzodiazepine therapy commonly leads to a 
‘withdrawal syndrome’ characterized by insomnia, anxiety, fatigue, irritability, light-
headedness, headache and gastrointestinal upset. These symptoms must be 
differentiated from rebound phenomena, which may also occur upon termination of 
therapy. Short-acting benzodiazepines (e.g. lorazepam) tend to have more severe 
withdrawal symptoms than of long-acting ones (e.g. diazepam) because of the more 
pronounced fluctuation in blood levels.  
 Buspirone is a well-tolerated drug, the most commonly reported side effects 
being transient dizziness, light-headedness, headache and gastrointestinal 
disturbances. It has a significant drug interaction with MAOIs.  
The SSRIs (Paroxetine, Fluoxetine, Sertraline, Fluvoxamine, Citalopram) and SNRI 
(Venlafaxine) have an impressive side-effect profile and this has contributed to their 
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widespread use.  Side effects include nausea, insomnia and agitation, but these are 
generally manageable and diminish over time. More significant is the association of 
the SSRIs with sexual dysfunction, in both men and women.  
 These effects are longer lasting and can occur in up to 40% of patients. 
  A withdrawal syndrome has also been observed with the SSRIs, characterized 
by dizziness, headache and irritability upon abrupt discontinuation. This is much less 
serious than observed with BZs and the symptoms typically resolve after a few days. 
Like buspirone, the SSRI / SNRI class has a delayed therapeutic effect and a 
potentially serious drug interaction with MAOIs. Clinically effective anxiolytics have 
several distinct modes of action and interacts with a number of important 
neurotransmitter systems. The efficacy of the benzodiazepines clearly implicates 
GABA in anxiety, whereas the clinical utility of buspirone and the SSRIs point to an 
important role for serotonin. The TCAs exert their therapeutic effects through 
inhibition of serotonin and norepinephrine reuptake and their efficacy suggests the 
involvement of both systems in anxiety disorders.  
 Although there are no clinically available drugs that modulate the 
cholecystokinin (CCK) and corticotrophinreleasing factor (CRF) systems, increasing 
evidence argues for their participation in the regulation of anxiety.  
  GABA (Ȗ-aminobutyric acid) is the major inhibitory neurotransmitter in the brain 
and is estimated to be present at 30-50% of all CNS synapses. Consequently, many 
important neurotransmitter systems are under the inhibitory influence of GABA, 
including the serotonin, norepinephrine, CCK and dopamine systems. Three types of 
GABA receptors have been identified87: GABAA, GABAB and GABAC. GABAA 
receptors belong to the super family of ligand-gated ion channels and mediate fast 
synaptic inhibition. GABAB receptors are G-protein-coupled receptors that can 
mediate inhibition or excitation and GABAC receptors appear to be similar to 
GABAA receptors but are localized predominantly in retina. GABA exerts its 
inhibitory effects in the CNS by binding to the GABAA receptor and opening the 
chloride channel at the center of the receptor. The resulting influx of chloride ions 
hyperpolarizes the neuron and reduces its sensitivity to incoming stimuli. Within the 
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GABAA receptor complex and in close proximity to the GABA binding site, there is 
an allosteric site, the benzodiazepine receptor (BZR), through which the BZs produce 
their effects.  
 Both depression and anxiety appear to be associated with a deregulation of 
serotonergic function at some level, a hypothesis supported by the clinical efficacy of 
the SSRIs in both disorder. Different serotonergic pathways and receptor subtypes are 
responsible for the modulation of anxiety and depression. Some of the major 5HT 
neuronal pathways originate in the raphe nucleus.They innervate a number of brain 
regions including the limbic system and in particular the septo-hippocampal system 
and the amygdale. Proposed that anxiety is a result of excessive serotonin activity in 
these specific brain regions. The serotonergic neurons arising from the dorsal raphe 
nucleus innervate the periacqueductal gray (PAG) and the amygdale and these may 
regulate adaptive responses to acute stress. On the other hand, 5HT neurons 
originating in the median raphe nucleus, which innervate the hippocampus, mediate 
resistance to chronic stress and failure of this pathway may contribute to depression. 
 Through their widespread blockade of the serotonin transporter, the SSRIs are 
known to increase serotonin levels at virtually every synapse in the CNS, yet the exact 
neuronal pathways and receptors through which their anxiolytic effect is ultimately 
produced remain unclear. Different 5HT receptor subtypes have been identified. Of 
these, seven subtypes have been implicated to a greater or lesser degree in anxiety: the 
5HT-1A, 5HT- 1B/D, 5HT-2A/B/C and 5HT-3 receptors. A survey of preclinical 
research into serotonergic agents as potential anxiolytics95 shows that 50% of studies 
over the past two decades involve 5HT-1A ligands, whereas 5HT-2 and 5HT-3 
compounds account for 15 and 13% of studies, respectively. Of all the serotonin 
receptors implicated in anxiety, the 5HT-1A receptor96 has been the subject of the 
most study. The only marketed anxiolytic acting directly on a serotonin receptor is 
buspirone, a 5HT-1A partial agonist. Activation of the postsynaptic receptors leads to 
neuronal inhibition in some limbic structures. Activation of the pre-synaptic auto 
receptors suppresses the firing rate of serotonin raphe neurons, thereby reducing 
serotonin turnover in the terminal fields.97, 98 Both modes of action are presumed to 
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contribute to the therapeutic effects of buspirone.99 1.9.3 Nor-epinephrine (NE) The 
majority of nor-adrenergic neurons in the brain are located in the locus cerulean (LC) 
and electrical stimulation of this region in animals leads to behaviors typical of an 
anxiety state. Increased NE levels are also associated with the somatic symptoms of 
anxiety, such as dry mouth, rapid heart rate and elevated blood pressure. Stressful 
events are known to increase NE release in brain regions intimately involved with 
emotional behavior including the hypothalamus, amygdale and LC and this increase is 
attenuated by diazepam. 
  Neuropeptides and Cholecystokinin (CCK) are most abundant 
neurotransmitter in the CNS. Two CCK receptor subtypes have been cloned as CCK-
A (Alimentary), which is located in the periphery and CCK-B (Brain).101 CCK-4 (a 
tetrpeptide) and CCK-8S (a sulfated octapeptide) are important neurotransmitters in 
the central CCK system and may have role in the mediation of anxiety response in 
animals and humans. Administration of CCK-4, a CCK-B agonist produce angiogenic 
response which can be blocked with CCK-B antagonists such as L-365,260 and CI-
988.103 b) Corticotrophin-Releasing Factor (CRF): It is a 41 amino acid peptide, 
mediates ACTH release from the hypothalamus and is intimately involved in the 
stress response. It is located in brain regions associated with anxiety, including the LC 
and the amygdale.  
 The modulatory effects of CRF are mediated through CRF-1 and CRF-2 
receptors. CRF-1 receptors are the dominant form in the CNS and hence the most 
frequently associated with neuropsychiatric disorders such as anxiety, depression and 
stress disorders. 
 Neuropeptide Y (NPY) receptors identified to date, Y-1 is the most strongly linked to 
the regulation of anxiety. This receptor is found in high densities in the brain, 
particularly in the cortex, thalamus and amygdale and Y-1 receptors in the latter 
structures are believed to mediate the anxiolytic effect of NPY.104, 108, 109 NPY has 
shown an anxiolytic effect in several animal mode, but mechanism of action is 
unclear. d) Glutamate receptors: The glutamate system is responsible for the most of 
the brain’s excitatory neurotransmission. Glutamate interacts with a number of 
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receptors, including the NMDA, AMPA, kainite and metabotropic glutamate 
receptors.  
 The latter receptor is coupled to G-proteins, whereas the others are directly 
linked to ion channels. Just as enhancement of GABA’s inhibitory action decreases 
anxiety, it might be expected that inhibition of glutamate’s excitatory functions would 
produce the same effect. Indeed, direct injection of NMDA antagonists into discrete 
brain regions produces anxiolytic. 
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2. REVIEW OF LITERATURES 
 Kushner, et al, (1994), evaluated whether alcohol outcome expectancies 
moderate the association between measures of anxiety and alcohol use. Student 
subjects completed questionnaire related to their level of anxiety, recent alcohol use 
patterns and outcome expectations to be tension reducing. Consistent with predictions, 
male Ss with tension reduction alcohol outcome expectancies showed a positive 
correlation between measures of anxiety and drinking behaviour than did male subject 
with low tension reduction outcome expectancies. The result of the study supports the 
Tension Reduction Hypothesis of stress induced drinking.  
 Brown, et al, (1991), conducted a study to explore the change in anxiety 
among abstinent male alcoholics. Results indicated that recently detoxified patients 
experience multiple anxiety symptoms. By the second week anxiety returned ro 
normal range and symptoms started decreasing. Elevated levels of anxiety symptoms 
were more common for patients with history of panic episodes or anxiety disorder. 
Relapsers scored higher on anxiety when compared to abstainers in the follow-up.  
 Blockland, et al, (1992), studied the effect of alcohol dn anxiety in rats. 12 
three months old rats were given 20% ethanol solution for 6 months as the only 
source of liquid; and the control group receiving tap water. 3 weeks after rhe cessation 
of treatment both groups were assessed on level of anxiety. It was found that anxiety 
was significunrly less in ethanol treated rats.  
 Keller, (1995), reported that there was no significant difference between the 
age of onset of addiction or choice or hug beriveen primary and secondary anxiety 
patients.  
 Allan, (1995), has quesrioned the assumption that anxiety reductioon is a 
major factor in the rtioloz\. &. of problem drinking. There are many studies which 
document the occurrence of anxiety symptoms in the problem drinkers. But the 
difficulty lies in deciding which comes first; the alcohol problems or the anxiety. 
Anxiety can be a consequence rather than a cause of heavy drinking.  
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 Hallen, (1996), conducted an experiment to study the adaptation to repeated 
restraint stress in rats treated with alcohol. Findings showed inability of ethanol 
treated rats to adapt in the stress schedule compared to the control. Results imply that 
excessive alcohol consumption may impair adaptation to stress and thus conceivably 
precipitate depression. 
  Brennan, et al, (1994), conducted a longitudinal analysis of the late life 
problem drinkers on personal and environmental risk factors as predictors of alcohol 
use, depression and treatment seeking. Study concluded that personal risk factors such 
as prior function, male unmarried. early onset of drinking and avoidance coping are 
independently predictive of poor outcomes. Among environmental risk factors, 
negative life events, chronic health, spouse stressors and having more friends who 
approved of drinking were independent predictors of poorer follow-up functioning 
and treatment seeking. Interaction between personal and environmental risk factors 
helped to predict subsequent alcohol consumption and treatment seeking. 
  Maharaj, (1990), investigated the relationship between alcoholism, 
depression. life events,stress. and purpose in life. Thirty-five first admission 
alcoholics nnd an equal number of Alcoholic Anonymous members were assessed on 
alcoholism, depression. >tress and purpose in life using objective measures. The 
results indicated significant differences between the two groups on drinking Prepared 
by BeeHive Digital Concepts for Mahatma Gandhi University behaviour, depression 
and purpose in life. However, no difference was noted between groups on stress. 
Positive correlation was obtained between drinking behaviour and depression, life 
events and purpose in life. 
  McCann, (1990), reported significantly higher prevalence rates of depression 
and obesity among family members of alcoholics compared to that of non alcoholics.  
 Windele and Biller, (1990), reported that depression was significantly 
associated with problem drinking.  
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 Akerlind and Hornquist, (1990), in a detailed evaluation of 78 alcoholics, 
concluded that change in loneliness was accompanied by change in well-being, mood 
related psychiatric variables and satisfaction with autonomy and life as a whole.  
 Benishek, et al, (1992), explored the relationship between global i 
psychopathology, depression, anxiety and alcoholism treatment outcome among 
males and females. It was found that psychopathology, particularly anxiety and 
depression differentially affects the substance abuse treatment response of men and 
women 
 Singh and Mehta, (1977), reported the psychotropic effect of Shankhpushpi. 
30 outdoor patients of anxiety neurosis were selected. They were given Shankhpushpi 
syrup in the dose of 30 ml per day in 3 divided doses (representing 50 g dry crude 
drug). The patients were reassessed on the following parameters of evaluate the effect 
of the treatment given after one month: (1) Clinical relief: the main symptoms scored 
in numbers by qualitative grading, (2) Psychological changes studied by (i) Total and 
differential anxiety level with the help of Middle Sex Hospital questionnaire, (ii) 
Neuroticism index as per MPI, (iii) Mental fatigue rate as per Joshi's digit cancellation 
test, (iv) Immediate memory span as per Joshi's digit renoxmce test, (3) Physiological 
changes viz. pulse rate, blood pressure and body weight, (4) Biochemical changes viz. 
plasma Cortisol, urinary catecholamines. A significant symptomatic relief was 
observed after one month of treatment are in regard to the major symptoms like 
nervousness, insomnia, weakness and fatigue dyspepsia, and general feelings of not 
being well. The mental fimctions as estimated by (1) mental fatigue rate and (2) 
immediate memory span showed significant improvement. Thus the study confirmed 
the claimed effect of this herbal medicine as a brain tonic and memory enhancer. 
 Mudgal, Rai, Singh, and Udupa, (1977), tested the immediate and 
cumulative tranquilizing effects of this herb. Neurohumoral changes were recorded as 
an index to study the status quo of brain. The aerial parts of Shankhpushpi were 
collected and the test extracts were prepared. Twenty four yoimg albino rats were 
selected, and divided into four groups comprising of 6 rats in each group. Two types 
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of experiments were as follows: (A) Short term experiments: (i) control 15 receiving 
only distilled water, (ii) treated group receiving one single injection of water soluble 
alcoholic extract of leaves and flowers of Shankhpushpi in the dose of 300 mg/kg 
weight intraperitonially one hour earlier to sacrifice. (B) Long term experiments: (i) 
control receiving only distilled water, (ii) treated group receiving the drug in the dose 
of 1.20 g/kg weight orally once in a day, for a period of 10 days. These rats were 
sacrificed on the lO*** day. In the short term experiment Shankhpushpi treated group 
showed significantly lower levels of acetylcholine and histamine. Statically there was 
no significant change found in the level of catecholamine in control and treated once. 
Shankhpushpi treated groups showed significantly lower levels of all the three 
neurohumors than control. This indicates a direct influence of Shankhpushpi on the 
central nervous system by the way of neurohumoral responses, thus strengthening the 
claim of Charak Samhita stating Shankhpushpi as a best neural tonic. 
  Hall, (1998), conducted a study, which provides scientific support for 
antioxidant activities of extracts of Shankhpushpi and substantiates the traditional 
claims for the usage of these drugs in stress- induced disorders. They found that 
Shankhpushpi contains volatile oil, n- triacontane, higher fatty alcohols, kaempferal, 
its 3-D- glucoside, 2-3- dydroxycinnamic acid, B- sitostoerol, carbohydrates such as 
glucose, rhamnose, sucrose, starch and potassium chloride, which enable the plant to 
be a brain tonic, in hypertension and as tranquilizer. Shankhpushpi has been foiind to 
have the nootropic and neuroprotective effects, as claimed in the following studies:  
 Dhingra and Volecha, (2007), conducted a study on Evaluation of the 
antidepressant-like activity of Convolvulus pluricaulis choisy in the mouse forced 
swim and tail suspension tests. This study investigates the effect of the petroleum 
ether, chloroform, and ethyl acetate fractions of the total ethanolic extract of 
Convolvulus pluricaulis Choisy (Family: Convolvulaceae) on depression in mice. The 
petroleum ether (25, 50 mg/kg), chloroform (25, 50, 100 mg/kg), and ethyl acetate 
(25, 50, 100 mg/kg) fi-actions were administered orally for 10 successive days to 
separate groups of Swiss young male albino mice. The effects of the extracts on the 
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mice's immobility periods were assessed in the forced swim test (FST) and tail 
suspension test (TST). The effects of reserpine (2 mg/kg i.p.), sulpiride (50 mg/kg 
i.p.), prazosin (62.5 microg/kg i.p.), and p-chlorophenylalanine (100 mg/kg i.p.) on 
the extracts' antidepressant-like effect in TST was 16 also studied. The extracts' 
antidepressant-like effect was compared with that of imipramine (15 mg/kg p.o.) and 
fluoxetine (20 mg/kg p.o.) administered for 10 successive days. Only the chloroform 
fraction in doses of 50 and 100 mg/kg significantly reduced the immobility time in 
both FST and TST. This fraction did not have significant effect on locomotor activity. 
Its efficacy was foimd to be comparable to that of imipramine and fluoxetine 
administered for 10 successive days. The chloroform fraction reversed reserpine-
induced extension of immobility period in FST and TST. Prazosin, sulpiride, and p-
chlorophenylalanine significantly attenuated the chloroform fraction-induced 
antidepressant-like effect in TST. The chloroform fraction of the total ethanolic 
extract of Convolvulus pluricaulis elicited a significant antidepressant-like effect in 
mice by interaction with the adrenergic, dopaminergic, and serotonergic systems. 
Bihaqi, Singh, Tiwari conducted a study in 2011. The study investigated the 
neuroprotective effect of Convolvulus pluricaulis aqueous extract (AE) against 
scopolamine (1 mg/kg body weight (bwt))-induced neurotoxicity in the cerebral 
cortex of male Wistar rats. The study was carried out on male Wistar rats (age 
matched, weight 250 ± 20 g). The present study investigated cognitive-enhancing 
property of AE using Elevated plus maze (EPM) (transfer latency [TL]) and Morris 
water maze (MAVM). Besides evaluating the effect of extract on neurochemical 
enzymes, in vivo antioxidant and free radical scavenging activities were also 
screened. All the measured parameters were compared with rivastigmine tartrate (1 
mg/kg bwt) which was taken as standard. Pretreatment of rats with AE (150 mg/kg 
bwt) significantly reduced scopolamine-induced increase in the TL in EPM, whereas 
in MWM, administration of exfract improved the impairment of spatial memory 
induced by scopolamine. The activity of acetylcholinesterase (AChE) was 
significantly inhibited by exfract within the cortex and hippocampus. Reduced 
activities or contents of glutathione reductase, superoxide dismutase, and reduced 
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glutathione within the cortex and hippocampus induced by scopolamine were elevated 
by the exfract. Taken together, it could be postulated that extract may exert its potent-
enhancing activity through both anti-AChE and antioxidant action. AE possesses 
neuroprotective potential, thus validating its use in alleviating toxic effects of 
scopolamine.  
 Kothiyal and Rawat, (2011), investigated the Comparative Noofropic effect 
of Evolvulus Alsinoides and Convolvulus Pluricaulis. The aim of the present study 
was to highlight the comparative nootropic effects of Evolvulus alsinoides and 
Convolvulus pluricaulis using two 17 validated models of memory namely jumping 
box and elevated plus maze. Rats were treated orally with vehicle (2% Tween 80 
suspention), standard treatment (Piracetam, 200mg/kg body weight) respectively, one 
hour prior to the evaluation of behavioral parameters. The results indicate that 
alcoholic extracts of Evolvulous alsinoides exhibited superior nootropic activity as 
compared to Convolvulus pluricaulis in terms of time spent in the enclosedarm in plus 
maze model and the mean avoidance response on the jumping box model. 
 Tanwar Godara, (2011), the antibacterial activity of methanolic extract of 
whole plant of Convolvulus pluricaulis was tested against Gram-negative bacteria like 
Escherichia coli ATCC 8739, and Gram-positive bacteria Staphylococcus aureus 
ATCC 6538, using Cup plate method with standard Tetracycline. The finding suggest 
methanolic extract of whole plant of Convolvulus pluricaulis has potent antibacterial 
activity against the pathogenic strains of Staphylococcus aeures and E.coli, exhibited 
significant wide spectrum of antibacterial activity against both Gram's positive and 
Gram's negative bacteria. From the study it was also concluded that Convolvulus, 
pluricaulis is more active against E. coli in comparison to S. aureus. Medicinal plants 
is becoming an important part of hidian research. Shankhpushpi is herb that have been 
used in India for hundreds of years for many disorders such as stress, anxiety, 
insomnia, and so many diseases. Following is the review of such studies. 
 Indurwade and Biyani, (2000), found that Shankhpushpi showed promise as 
a safe, effective remedy for anxiety. They conducted the research on 110 adults of age 
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group 25- 45 years. The subjects were divided into two groups- one as experimental 
group and received Shankhpushpi treatment, where as the other group was control and 
received placebo. The treatment was continued for 4 weeks with doses of 120 mg 
daily. The assessment was done with the help of Hamilton Anxiety Scale (HAS) in 
before and after conditions. The findings showed that the experimental group 
experienced reduced anxiety than the control group. S 
 Ubramani, Anand and Muralidham, (2005), studied the effect of 
Convolvulus Pluricaulis in Obesessive Compulsive Disorder. The study investigated 
the methanolic extracts of convolvulus pluricaulis (MECP) action on OCD with 
animal models by using invivo pharmacological evaluations such as Marble burying 
behavior, Hole board test, Rota- rod test using mice. They 18 used seven groups of 
mice. All the three tests were made on the seven groups. First group served as control. 
Second and third groups were treated with 15 mg/Kg and 30 mg/Kg of fluoxetine 
which is a standard drug and also it is a selective serotonin reuptake inhibitor (SSRIs). 
Then fourth and fifth groups were treated with 2.5 mg/Kg and 5 mg/Kg of diazepam 
which is an anxiolytic -sedative drug usefiil in the symptomatic relief of anxiety and 
tension states it serves as a negative control. Sixth and seventh groups were treated 
with 200 mg/Kg and 400 mg/Kg MECP. The results show that the MECP can 
modulate serotonin or dopaminergic levels, which is the major pathway of OCD 
pathophysiology.  
 Cerevenka and Jahodar, (2006), conducted a pre- post, randomized, 
placebo- controlled study. As a sample, 30 patients with anxiety were given 30 ml of 
Shankhpushpi syrup daily for three months. Testing was done three times i.e. after 1 
month, 2 months, and after 3 months of the treatment with the help of Hamilton 
Anxiety Scale. After one month, their anxiety levels decreased by 20 percent, after 2 
months the effect of treatment was more visible and the patients felt significantly 
better, after the third testing, the anxiety levels of the patients was reduced by 56 
percent. This was concluded that the herb Shankhpushpi is more effective when given 
for long duration. 
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  Ernest, (2006), conducted a study related to anxiety treatment. He gave 28 
people of age group 28-50 years diagnosed with anxiety 50 mg daily of herbal 
formula with Shankhpushpi as a primary ingredient. The patients were diagnosed with 
Walmyr Clinical Anxiety Scale (WACS). After sixth months of the treatment, 91 
percent of the patients felt reduced anxiety and 60 to 70 percent could sleep and 
concentrate better. Symptoms like nervousness also decreased. Saeed, Bloch, and 
Antonacci (2007) examined the effect of herbal medicine Shankhpushpi on insomnia. 
They were given 10 mg dose of diazepam (an anti- anxiety drug), a placebo, or one of 
several forms of Shankhpushpi to 25 albino rats. The rats that received an alcohol 
extracts of Shankhpushpi slept for 74 minutes, significantly longer than those who 
were given the placebo (52 minutes) and only seven minutes less than those who took 
diazepam (81 minutes). Other forms of Shankhpushpi were not so effective. 19 
Shankhpushpi have much relevance to many aspects of human life. It has been found 
to play a major role in memory, learning, other cognitive functioning, and other 
mental functions. Summary of some of the research papers is given below to support.  
 Prakash and Sinha, (1988), studied the effect of Convolvulus microphyllus 
(a synonymous of Convolvulus pluricaulis) in complex cognitive task in terms of 
increment in peptide load in the brain. A total of 27 albino rats in three groups (thus 
having 9 rats in each group) were tested in Hebb-William Maze task with no 
obstruction, one, two and three obstructions. Time seriescontrol group design was 
employed. The subjects were treated with injectable form of analog of 
nouropeptidgeric substance (Sitosterol) obtained from Convolvulus microphyllus. It 
was observed that administration of 100 mg sitosterol 6 Hs. before training facilated 
the acquisition both in terms of time taken and errors committed. Similarly, the role of 
this drug as a promotor of the brain protein synthesis was confirmed when the 
subjects were treated before retention. After post experimental conditions the rats 
were sacrificed and the content of brain protein obtained. An increase in brain protein 
was found in all groups given the experimental treatment. This increment was due to 
administration of Convolvulus microphyllus, Dubey, Pathak, and  
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 Gupta, (1994), studied the confirmed effect of Brahmi (Bacopa monniera) and 
Shankhpushpi (Convolvulus pluricaulis) on memory and overall learning ability. 
Sixteen school going children (aged 10-19 years) selected on the basis of their poor 
educational performance were given these substances in doses of 200 mg daily for six 
months. An equal number of children served as control and received only placebo. A 
significant improvement in memory was observed in the Shankhpushpi treated group. 
None of the children showed any adverse effects.  
 Priyanka and Batra, (2003), investigated the role of Shankhpushpi in 
memory enhancement. This was a pre- post, double blind, placebo- controlled, 
parelled- group design based study. Sixty four subjects of age group 19-26 years were 
administered either Shankhpushpi or placebo for the period of 15 days and 30 days. 
The testing was done with the help of Forward Digit Span Task and Backward Digit 
Span Task, 30 words recall test and serial learning task before and after treatment. 
Results indicated that Shankhpushpi enhanced STM, LTM, Retrival and storage of the 
treated group. The placebo group's score was found 20 insignificant on all the tests in 
both the durations. The study indicated that even 15 days were enough to see the 
improvement due to administration of Shankhpushpi.  
 Priyanka and Batra (2004) investigated the effect of Shankhpushpi on 
memory. In this study, a multi group, pre-post, double blind, placebo control design 
was employed. As a sample, 200 normal adults of age group 19-25 years were 
selected. The participants were divided into 10 groups (5 controls and 5 experimental 
groups). There were 20 subjects in each group. The subjects were given either 3.5 gm 
of Shankhpushpi or 3.5 gm of an ordinary powder with honey followed by a glass of 
milk for different durations (i.e. 15 days, 30 days, 60 days, 120 days, and 180 days). 
Forward digit span (FDS), Backward digit span (BDS), 30 words recall test. Serial 
learning task were taken for the testing. A memory enhancement (of both STM and 
LTM) after the duration of 30 days was observed. Results of the treatment for 120 and 
180 days were found to be the best. The improvement went to increasing with an 
increased duration of administration of Shankhpushpi. It was concluded that 
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Shankhpushpi enhanced memory and cognitive fimctions such as attention, storage 
and retrieval capacity of short term memory and long term memory, speed of 
learning, encoding for item to get registered in LTM. A residual effect was also 
observed after 60 days of the administration of Shankhpushpi except the complex task 
of serial learning, up to 2 months only. For complex task a residual effect after 120 
days administration was observed up to 2 months. It was also important to be noted 
that there was foimd no side effect of Shankhpushpi even used for longer durations 
i.e. 180 days or up to six months even in a single subject. 
  Kapse, (2005), had done single blind control clinical trial to assess cognition 
enhancing (Medhya) effect of Shankhpushpi (Convolvlus Pluricaulis) on 90 patients. 
For that study, Shankhpushpi tablets to group A was given in dose 3 gms/day in two 
divided doses for the duration of six months. Group B was control group in which 
tablets of Shankhpushpi bheda (Evolvulus alsinoides Linn) in same dose and duration 
was given. The group C was placebo group was received starch powder by same 
maimer. The scales used for assessment of the effect were - (1) Behavior profile (i) 
Standardized symptom checklist (SSCL) (ii) Child Behavior checklist - Standard 
version (CBCLSV) (2) Effect of cognitive fimction by NVIT (3) Effect on metal 
faculties by NIMHANS proforma. Criteria of assessment were according to relief of 
symptoms of behavior disorders, improvement in fimctions of mana and reduction of 
21 manodhamiya Vega and improvement in PR. In this study Convolvulus pluricaulis 
type of shankhapi showed significant results due to its cognition enhancing (Medhya) 
and manasarogahar activity. The test drug showed effective relief in symptoms of 
behavior disorders of adolescent age group. It had been more effective in enhancing 
grasping capacity and intellectual power (Dhi and dhruti).  
 Agarwal, Sharma, Rajamanickam, and Dubey (2006), conducted a research 
on Age Consistent Cognitive Decline - An Ayurvedic Pharmacological Management. 
As a sample, 61 aged subjects of both sex with an age range of 62-75 years were 
selected. 28 aged had cognitive deficits particularly the memory loss. Whereas 33 
were normal aged. The subject of both group were treated with organic extract of 
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Bacopa monnieri in effective doses continuously for six months and evaluated on 
various neuropsychological parameters. The results obtained at the end of six months 
revealed beneficial effect in improving memory and attention span and also associated 
behavioural problems among demented elderly people. The neuro-chemical loss was 
checked and enhanced in senile dementia cases. The test drug has potentiality to 
improve memory and other cognitive deficits among the aged suffering fi-om 
dementia and associated behavioiu-al problems. 
  Batra, (2008),  investigated the effect of Shankhpushpi on mentally retarded 
population. As a sample, 5 male mentally retarded subjects were selected out of 20 
such Subjects on single and successive command test in Dementia Rating Scale 
(DRS-2) by Steven Mattis. Those who could follow these commands those 5 Subjects 
were selected. These subjects were administered upon FDS and BDS task to assess 
their short term memory and Quality of Life Scale by Meryl Brod. Now these 
Subjects were given Shankhpushpi daily and retested after 10 days and 45 days. The 
results clearly showed an improved memory and wonderful quality of life. The 
Subjects were also tested after 40 days of discontinuing the consumption of 
Shankhpushpi to a study of residual effect. A study conducted in 2008 by Batra, 
Kumar, Rawat, and Batra examined the effect of Shankhpushpi on Short Term 
Memory and Long Term Memory. They conducted the research on a sample of 20 Ss 
studing in IX and X was selected. They were given 3.5g of Shankhpushpi powder for 
40 days. These subjects were tested on FDS, BDS and Serial Learning Task before 22 
and after the administration of Shankhpushpi. The measure were computed on each 
task for both duration, i.e. 20 and 40 days. Results indicated an improvement in both 
FDS and BDS. The number of trials taken in Serial Learning Task reduced. A 
retention test after 24 hrs of Serial Learning Task was also taken in both pre and post 
testing. There was an improvement in the number of items recalled. These results 
indicate that the Shankhpushpi improves both the Short Term Memory and Long 
Term Memory. The rate of improvement after 20 days of consuming Shankhpushpi 
was higher than the rate of improvement between 20 and 40 days.  
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 Rajesh and Batra, (2009), conducted a double-blind, pre-post, placebo 
controlled study. They investigate the effect of Shamkhpushpi on dementia rating and 
quality of life amongst the patients of dementia. As a sample, 80 already diagnosed 
patients, 40 belonging to Senile Dementia of Alzheimer's Type (SDAT) and 40 
belonging to Multi-infarct Type (MIT) were selected. They administered either 
Shankhpushpi powder or placebo (3.5gm/day) for a duration of 4 months. The 
participants were divided into 4 groups (2 control and 2 experimental groups).The 
assessment was done with the help of Dementia Rating Scale-2 (DRS-2) by Steven 
Mattis, to assess the levels of cognitive fimctioning for individual with brain 
dysfiinction, and Dementia Quality of Life Instrument (DQoL) by Meryl Brod, to 
assess the quality of life of patients with dementia. The patients were assessed three 
times, i.e. firstly in the starting, then after 2 months, and then after 4 months 
administration of herbal medicine. The herbal medicine Shankhpushpi led to an 
improvement in both types of dementia. It was found that on DRS-2, most of the 
dimention such as attention, initiation/perseveration, conceptualization showed 
significant improvement due to administration (both duration) of Shankhpushpi. It is 
observed in total scores of DQoL, Shankhpushpi improved the quality of life both 
dementia type after 2 and4 months. It was also found that Shankhpushpi improved 
self-esteem, positive affect, feelings of belonging significantly. And, on many tasks, 
the effect goes on increasing with the increasing duration.  
 Rawat and Kothiyal, (2010),  investigated the neuropsychopharmacological 
effects of various reported species of Shankhpushpi - Evolvulous alsinoides 
Linn.,Convolvulous pluricaulis Sieb.and Clitorea tematea Linn, on learning and 
memory processes. Morris Water maze was employed to evaluate learning and 
memory parameters. Alcoholic extract of Evolvulous alsinoides Linn., Convolvulous 
pluricaulis Sieb. and Clitorea tematea Linn, were 23 prepared and administered to rats 
per oral , at a dose of 250 and 500 mg/kg body weight . Piracetam (200 mg/kg body 
weight ip) was used as standard drug. The animals were subjected to training for eight 
days. At the end of trial session the animals were subjected to spatial memory test by 
measuring the time spent in the target quadrant.Amongst the three species of 
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Shankhpushpi ethanolic extract of Evolvulous alsinoides seemed to be the best since 
time spent in target quadrant after the training session was the maximum. Results 
indicate that all the three species exhibited a dose dependent nootropic effect.  
 Shah and Goyal, (2010), conducted a study on Comparative clinical 
evaluation of herbal formulation with multivitamin formulation for learning and 
memory enhancement. The objective of the study was to clinically evaluate 
polyherbal formulation (PHF) and compare with multivitamin (MH) preparations 
used as learning and memory enhancer. It was randomized, placebo controlled, double 
blind clinical study approved by Institutional Human Ethics Committee. Forty- seven 
healthy human volunteers from colleges of Mehsana (18-24 years) ready to sign 
informed consent form were included in study. All these subjects were given either on 
capsule of placebo or two capsules of PHF (500mg) at night or MV (SOOmg) 1 
capsule two times a day for a period of three months. They were monitored for 
neuropsychological tests initially, after first and third month of active treatment with 
PHF/MV. Results showed that there was significant increase in IQ score and short 
term memory score in PHF treated group between 0 and 90 days treatment. In the 
other battery test significant alterations were observed in all three groups. Our data 
suggest both PHF and MV supplementation specifically improves learning and 
memory as compared to placebo in healthy young subjects. PHF appears to be more 
active than MV. The present study Cognition boosting effect of Canscora decussata (a 
South Indian Shankhpushpi) conducted by  
 Sethiya and Mishra (2011), investigated the effect of Canscora decussata 
Schult (CD), which is regarded as Shankhpushpi, for its effects on learning and 
memory in rodents. The extract was fiirther studied for its in vitro 
acetylcholinesterase (AChE) inhibitory potential which can correlate with its 
cognition boosting effect. Ethanol extract of CD was analyzed by high performance 
thin layer chromatography (HPTLC) and high performance liquid chromatography 
(HPLC). Ethanol extract of CD was investigated for its AChE enzyme inhibitory 
activity. Nootropic activity using Elevated plus maze apparatus, 24 passive avoidance 
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(Cook and Weidley's pole climbing, step down) paradigms and active avoidance (two 
compartment shuttle box) test were used to learning and memory. HPTLC and HPLC 
fingerprinting of ethanol extract revealed presence of mangiferin as its main 
constituent. It was found that CD potentially inhibits AChE with 50% inhibitory 
concentration (IC50) of 165.667 ±0.213 mg/ml. It was foimd that groups (n = 6), 
receiving ethanol extract in doses of 200 and 400 mg/kg p.o. significantly reversed the 
amnesia induced by scopolamine (0.3 mg/kg i.p.). Nootropic activity was compared 
using piracetam (100 mg/kg p.o.) as the standard. Ethanol extract of CD showed 
significant effects on learning behavior and memory enhancement as evidenced from 
the experiments performed. The activity may be attributed to the presence of various 
xanthones and mangiferin, a polyphenolic xanthone. Not much research has been 
published on Shankhpushpi. There are limited studies on the herb, which throw light 
on its cognition enhancing properties. To conclude the review of various studies it is 
clear that Convolvulus pluricaulis (CP) has been widely screened for its various 
pharmacological activities. It has relatively well documented neuropharmacological 
actions such as nootropic, antistress, anxiolytic, antidepressant, anticonvulsant, 
tranquilismg and sedative activities which justify its use in CNS diseases in the 
Ayurvedic system of medicine. It has antimicrobial, antipyretic, anti-inflammatory, 
analgesic, diuretic, antidiabetic and insecticidal properties. The various reported 
pharmacological activities of Convolvulus pluricaulis highlight the therapeutic 
potential of Convolvulus pluricaulis and limitations in our knowledge of its claimed 
traditional Indian usage. With this background one may now proceed towards the 
formulation of problem and hypotheses for the study. 
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3.DRUG PROFILE 
BERBERINE HYDROCHLORIDE 
 Berberine is a plant alkaloid with long standing history of medicinal use in 
traditional Chinese, Native American medicine as well as in indigenous Indian 
medicines. It is bright yellow colored Iso quinolone alkaloid and is a chief alkaloid 
found in roots, stem and bark of bereberis species. 
CAS No  :  633-65-8 
Molecular formula :  C20H18ClNO4 
Molecular Weight : 371.817 g/mol 
 
Fig 1. Structure of Berberine 
 Berberine Hydrochloride is the orally bioavailable, hydrochloride salt form 
of berberine, a quaternary ammonium salt of an isoquinoline alkaloid and active 
component of various Chinese herbs, with potential antineoplastic, radiosensitizing, 
anti-inflammatory, anti-lipidemic and antidiabetic activities. Although the 
mechanisms of action through which berberine exerts its effects are not yet fully 
elucidated, upon administration this agent appears to suppress the activation of 
various proteins and/or modulate the expression of a variety of genes involved in 
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tumorigenesis and inflammation, including, but not limited to transcription factor 
nuclear factor-kappa B (NF-kB), myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma 2 
(Bcl-2), B-cell lymphoma-extra large (Bcl-xl), cyclooxygenase (COX)-2, tumor 
necrosis factor (TNF), interleukin (IL)-6, IL-12, inducible nitric oxide synthase 
(iNOS), intercellular adhesion molecule-1 (ICAM-1), E-selectin, monocyte 
chemoattractant protein-1 (MCP-1), C-X-C motif chemokine 2 (CXCL2), cyclin D1, 
activator protein (AP-1), hypoxia-inducible factor 1 (HIF-1), signal transducer and 
activator of transcription 3 (STAT3), peroxisome proliferator-activated receptor 
(PPAR), arylamine N-acetyltransferase (NAT), and DNA topoisomerase I and II. The 
modulation of gene expression may induce cell cycle arrest and apoptosis, and inhibit 
cancer cell proliferation. In addition, berberine modulates lipid 
and glucose metabolism. 
 Alkaloid berebrine has been added in the armamentarium of drugs used in DM 
type 2. It is no more a secret that India will be bearing the tag of DM capital of the 
world. DM is a disorder affecting multiple organs with propensity for infections of 
various kinds due to underlying mechanisms like hyperglycemia, oxidative stress etc. 
Hence it is going to be an added advantage to choose the drug for DM which has also 
got antimicrobial activity like berberine hydrochloride. None of the current anti 
diabetics can boast about additional antimicrobial action like berebrine hydrochloride. 
 Wang reported in 2009 that berberine (100 mg/kg) restored the vascular 
endothelial function by increasing nitric oxide levels in rats in which diabetes had 
been induced by a combination of high-fat diets and treatment with 
streptozotocin.23 Wang et al reported similar benefits in a similar rat model in 2011. In 
this case, the diabetic rats were treated with ascending doses of berberine: 0 (control), 
50, 100, and 150 mg/kg/d of berberine for 6 weeks. The hypoglycemic effects of 
berberine were evidenced in the fasting blood glucose levels and insulin-sensitizing 
effects.24 
 In 2008, Yin reported the results of 2 human trials in the journal Metabolism 
on patients newly diagnosed with type-2 diabetes who were randomly treated to take 
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either berberine or metformin (500 mg 3 times a day) in a 3-month trial. The 
hypoglycemic effect of berberine was similar to that of metformin. In the first study 
(n=36), the hypoglycemic effect of berberine was similar to metformin with a 2% 
decrease in A1c (P<0.01) and fasting blood glucose (-8.7 mmo/L, P<.01). In the 
second study (n=48), patients with poorly controlled type-2 diabetes took berberine 
for 3 months. Hemoglobin A1c decreased from 8.1% to 7.3% (P<.001).25 
 A recent meta-analysis by Dong et al combined data from 14 randomized trials 
involving 1,068 participants. Treatment with both berberine and lifestyle modification 
showed significant hypoglycemic and antidyslipidemic benefits. The effects did not 
differ from those obtained by the standard hypoglycemic drugs metformin, glipizide, 
or rosiglitazone.26Berberine has been studied and shown to be effective in treating 
other conditions that respond to metformin. 
 In January 2012, the European Journal of Endocrinology published results of 
a clinical trial that found berberine compared favorably with metformin when used to 
treat women (n=89) with polycystic ovary syndrome (PCOS).27 A year earlier, an 
article in Fertility and Sterility reported that berberine reduces insulin resistance in 
ovarian theca cells and decreased their excessive testosterone production.28 
 Berberine, like metformin, appears to be useful for treating metabolic 
syndrome. Not only does it reduce insulin resistance but it also normalizes the lipid 
profiles characteristic of the condition.29 
 Berberine, like metformin, can help reduce the side effect of weight gain 
triggered by antipsychotic medications.30, 31 
 Researchers have become intrigued by the potential benefit metformin has in 
treating cancer. It is possible that berberine will have a parallel action. 
 Berberine increases expression of insulin receptors and so reduces insulin 
resistance.32,33 A 2009 study in China suggested that a synergistic action occurs when 
berberine is combined with metformin or 2,4-thiazolidinedione (THZ) (a peroxisome 
proliferator-activated receptor [PPAR] activator used to treat diabetes) and might 
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allow a reduction in the amount of these drugs required for treatment and so reduce 
the risk of toxicity.34 
 If one thinks of AMPK activation as “something that reverses metabolic 
syndrome,” then several other aspects of metabolic syndrome and potential actions for 
berberine come to mind. Aside from hyperglycemia, there are 3 other hallmarks of 
metabolic syndrome: dyslipidemia, fatty liver, and inflammation. 
 A December 2004 article described berberine as “a novel cholesterol-lowering 
drug” that worked through a “unique mechanism distinct from statins.” The authors 
had given berberine to 32 hypercholesterolemic patients for 3 months. The treatment 
reduced serum cholesterol by 29%, triglycerides by 35%, and LDL-cholesterol by 
25%.35 
 A 2009 study reported that in rats, AMPK activation triggered by berberine 
prevented the development of fatty liver.36 This was followed in 2011 by a 
randomized controlled trial of 60 humans with fatty liver disease. The tracking of 
numerous biomarkers showed that 3 months of “berberine can obviously improve the 
conditions.” Liver ultrasounds of the study participants showed a 70% improvement. 
Total cholesterol and triglycerides also decreased significantly in this trial. These 
patients took 0.5 g of berberine twice per day.37 
 According to a randomized controlled trial conducted in 2008 with diabetic 
rats in which dyslipidemia had been induced with a combination of streptozotocin and 
a high-fat diet, “Berberine reduced diabetic rats’ body weight, liver weight and liver 
to body weight ratio. Berberine restored the increased blood glucose, hemoglobin 
A1c, total cholesterol, triglyceride, low density lipoprotein-cholesterol, apolipoprotein 
B and the decreased high density lipoprotein-cholesterol, apolipoprotein AI levels in 
diabetic rats to near the control ones. Berberine alleviated the pathological 
progression of liver and reverted the increased hepatic glycogen and triglyceride to 
near the control levels.”38 
 A 2010 human clinical trial analyzed changes in serum metabolites, 
particularly free fatty acid levels, in 60 patients with type-2 diabetes who had taken 
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berberine. The berberine group had significantly lower levels of free fatty acids, 
chemicals that are toxic to the pancreas and linked with insulin resistance.39,40 
 Berberine’s lipid-lowering mechanism of action is different from that found in 
the statin drugs.41 Combining berberine with statin drugs has a synergistic effect and 
is more effective than using either alone. In 2008, a Chinese researcher reported in the 
journal Metabolism results of a study that combined berberine with simvastatin. The 
researchers began by treating hyperlipidemic rats with a combination of both agents 
together or as monotherapies; the combination of both agents reduced cholesterol by 
46% while simvastatin alone reduced cholesterol by 28% and berberine alone by 
27%. Combination therapy was then tried on 63 hypercholesterolemic patients. The 
combined therapy lowered LDL cholesterol 32% more than either monotherapy. 
Similar benefits were seen with total cholesterol and triglycerides.42 
 Similar synergistic action was seen in an experiment using hyperlipidemic 
hamsters and treating them with a combination of berberine and plant stanols.43 
While improving lipids may improve cardiovascular disease (CVD) risk, berberine 
has other beneficial actions that lower CVD risk. It improves arterial endothelial 
function and suppresses proinflammatory cytokines, actions that should improve heart 
health.44–48 
 Adding berberine to cultures of human macrophage–derived foam cells, which 
had been induced by oxidized LDL, significantly inhibits the effect of oxidized LDL 
in a dose- and time-dependent manner and inhibits the expression of its lectin-like 
receptor (LOX-1) actions suggesting that berberine could be useful in treating 
atherosclerotic diseases.49 
 A July 2003 study published in the American Journal of Cardiology examined 
the use of berberine in congestive heart failure (CHF). The authors randomly divided 
156 patients with CHF into 2 groups. All patients were treated with conventional 
therapy but 1 group of 79 patients was also given berberine at a dose of 1.2 to 2.0 
grams per day. After 8 weeks of berberine treatment, “there was a significantly 
greater increase in left ventricular ejection fraction, exercise capacity, improvement of 
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the dyspnea-fatigue index, and a decrease of frequency and complexity of VPCs 
[ventricular premature complexes] compared with the control group. There was a 
significant decrease in mortality in the berberine-treated patients during long-term 
follow-up (7 patients receiving treatment died vs 13 on placebo, P<.02).” 
Proarrhythmia was not observed, and there were no apparent side effects.”50 
 A second chemical pathway of interest when considering therapeutic 
applications of berberine to diabetes is the aldose reductase pathway. Aldose 
reductase is the rate-limiting enzyme in the polyol pathway. It reduces glucose to 
sorbitol using NADPH (nicotinamide adenine dinucleotide phosphate) as a cofactor. 
Sorbitol is then metabolized to fructose by sorbitol dehydrogenase. In healthy people, 
only a small amount of glucose (less than 3%) moves through this pathway. However, 
in the presence of high glucose levels, as much as 30% of total glucose will follow 
this path. In diabetics, this abnormal flow of glucose down the polyol pathway leads 
to the accumulation of large amounts of sorbitol, which in turn leads to both osmotic 
and oxidative stress in the tissues where sorbitol accumulates.51 Aldose reductase 
plays a significant role in much of the pathology caused by diabetes, including 
diabetic neuropathy, retinopathy, and nephropathy.52 
 Lee’s 2002 report in the Journal of Agriculture and Food Chemistry revealed 
that berberine is an aldose reductase inhibitor.53 
 In 2 separate articles published in 2008, Liu reported that berberine extracts 
protected or helped repair the kidneys of diabetic mice partly through aldose reductase 
inhibition.54,55 Berberine reduced oxidative stress in the kidneys.56 
 Aldose reductase plays a role in diabetic cataract formation, and inhibition 
helps prevent cataract formation.57 
 Because of these properties, berberine alkaloids “would clearly have beneficial 
uses in the development of therapeutic and preventive agents for diabetic 
complications and diabetes mellitus.”58 
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 A number of other chemical pathways have been delineated that underlie 
berberine’s antidiabetic actions. Berberine inhibits dipeptidyl peptidase-4 (DPP IV) 
and human protein tyrosine phosphatase 1B (h-PTP 1B).59 It suppresses production of 
intestinal disaccharidases, reducing sugar digestion and absorption.60 It improves 
glucose metabolism by inducing glycolysis.61 It also increases glucose transporter-4 
(GLUT-4) and glucagon-like peptide-1 (GLP-1) levels.62 The peptide GLP-a is more 
commonly known by the name incretin.63Historically, incretin is the first hormone to 
have been identified. It is secreted by the small intestine after eating and triggers 
release of insulin. Exenatide (Byetta) and liraglutide (Victoza), both incretin 
mimetics, have been developed and are now prescribed to treat type-2 diabetes.64 
Absorption 
 Berberine was thought to be poorly absorbed across the gut wall. 
Pharmacokinetic researchers have certainly found low plasma concentrations—levels 
so low that “the remarkable variety of pharmacological effects exerted by Ber[berine] 
at blood concentrations below the effective dose required for activity in vitro has been 
regarded with considerable skepticism.”65 
 The pharmacokinetics of berberine are “obscure because plasma 
concentrations after p.o. administration are too low to detect using general analytic 
approaches such as HPLC.”66 As a result, it had been assumed that very little if any 
berberine is absorbed. 
 It now appears that the situation is more complex; berberine actually appears 
to be well absorbed. The confusion lies in the fact that it is quickly metabolized. 
Blood clearance is so fast and biotransformation in the liver so rapid that berberine 
disappears from the blood faster than it can be measured. Berberine metabolites may 
be responsible for berberine’s biological action. 
 Most berberine is metabolized in the liver through phase I demethylation and 
phase II glucuronidation, after which the metabolites are excreted with the bile. 
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 Considerable interest has been directed toward creating nanoparticle delivery 
systems for berberine, the assumption being that therapeutic effects will increase with 
increased absorption. These delivery systems fall into 3 general types: solid lipid 
nanoparticles, nanoemulsions, and liposomes.67 
 Wang et al compared the blood sugar–lowering effect of a nanoemulsion made 
of phosphatidyl-choline micelles and berberine against intravenously administered 
and plain oral berberine in diabetic mice. Intravenous injection of a berberine solution 
lowered blood sugar by 22% while the oral nanoemulsion of berberine lowered blood 
sugar levels by 57%. The blood glucose–lowering effect of standard oral berberine 
did not reach statistical significance in this trial.68 
 Results like these are exciting; they suggest the potential for much stronger 
impact. Enhanced oral delivery systems that could increase the clinical effectiveness 
of berberine will likely be introduced in the coming years. 
 While the known clinical applications for berberine are diverse and becoming 
more so over time, there are a few generalizations we might make that will allow us to 
understand berberine’s potential. Berberine activates AMPK in a manner similar to 
how exercise stimulates increased strength and weight loss. Thus, any condition that 
would be favorably impacted by a patient losing weight and/or exercising more may 
be impacted favorably by oral berberine supplementation. It makes sense to consider 
using berberine in patients with insulin resistance, pre-diabetes, diabetes, metabolic 
syndrome, hypertension, heart disease, dyslipidemia, cancer, depression, and other 
neuropsychiatric diseases. We also can look at conditions improved by other AMPK-
activating drugs, in particular metformin, to help make educated guesses of other 
possible applications that may soon be revealed. 
CHITOSAN 
Nonproprietary names 
 BP: Chitosan hydrochloride  
 PhEur: Chitosani hydrochloridum 
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Synonyms 
 
2-Amino-2-deoxy-(1,4)-b-D-glucopyranan; deacetylated chitin; deacetylchitin; b-
1,4-poly-D-glucosamine; poly-D-glucosamine; poly-(1,4-b-D-glucopyranosamine). 
 
Chemical name and CAS registry number 
 
Poly-b-(1, 4)-2-Amino-2-deoxy-D-glucose (9012-76-4) 
Description 
 
Chitosan and chitin are polysaccharide polymers containing more than 5,000 
glucosamine and acetyl-glucosamine units, respectively and their molecular weights 
are over one million Daltons. Chitin is found in fungi, arthropods and marine 
invertebrates. Commercially, chitin is derived from the exoskeletons of crustaceans 
such as shrimp, crab and other shellfish. Chitosan is obtained from deacetylation of 
chitin, the cellulose like polysaccharide polymer, consisting mainly of unbranched 
chains of N-acetyl-D-glucosamine. Deacetylated chitin, or chitosan, is comprised of 
chains of D-glucosamine. When ingested, chitosan can be considered a dietary fibre. 
Chitosan occurs as odourless, white or creamy white powder or flakes. Fibre 
formation is quite common during precipitation and the chitosan may look like cotton. 
 
Chiosan is obtained by the alkaline deacetylation of chitin. Chitosan molecule 
is a copolymer of N-acetyl-D- -1, 4-
linked D-glucos-amine with a high degree of N-acetylation, a structure very similar to 
that of cellulose, except that the acetylamino group replaces the hydroxyl group on the 
C-2 position. Thus chitosan is poly (N-acetyl-2-amino-2-deoxy-D-glucopyranose), 
where the N-acetyl-2-amino-2-deoxy-D-glucopyranose (or Glu-NH2) units are linked 
-glycosidic bonds (Hejazi and Amiji, 2003). 
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Empirical formula and molecular weight 
 Partial deacetylation of chitin results in the production of chitosan, which is a 
polysaccharide comprising copolymers of glucosamine and N-acetylglucosamine. 
Chitosan is the term applied to deacetylated chitins in various stages of deacetylation 
and depolymerization and it is therefore not easily defined in terms of its exact 
chemical composition. A clear nomenclature with respect to the different degrees of 
N-deacetylation between chitin and chitosan has not been and as such chitosan is not 
one chemical entity but varies in composition depending on the manufacturer. In 
essence, chitosan is chitin sufficiently deacetylated to form soluble amine salts. The 
degree of deacetylation necessary to obtain a soluble product must be greater than 80–
85 %. Chitosan is commercially available in several types and grades that vary in 
molecular weight by 10000–1000000, and vary in degree of deacetylation and 
viscosity  
 
 
 
 
 
 
 
Fig.2. Structure of chitosan  
Functional category 
 Coating agent; disintegrant; film forming agent; mucoadhesive; tablet 
binder; viscosity increasing agent. 
 
Applications in pharmaceutical formulation or technology 
Chitosan is used in cosmetics and is under investigation for use in a 
number of pharmaceutical formulations. The suitability and performance of 
chitosan as a Component of pharmaceutical formulations for drug delivery 
applications has been investigated in numerous studies 
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Description 
 Chitosan occurs as odourless, white or creamy white powder or flakes. Fiber 
formation is quite common during precipitation and the chitosan may look ‘Cotton 
like’. 
 
 
4.1.10. Typical properties 
 Chitosan is a cationic polyamine with a high charge density at pH <6.5; and so 
adheres to negatively charged surfaces and chelates metal ions. It is a linear 
polyelectrolyte with reactive hydroxyl and amino groups (available for chemical 
reaction and salt formation. The properties of chitosan relate to its polyelectrolyte and 
polymeric carbohydrate character. The presence of a number of amino groups allows 
chitosan to react chemically with anionic systems, which results in alteration of 
physicochemical characteristics of such combinations. The nitrogen in chitosan is 
mostly in the form of primary aliphatic amino groups. 
 
 Chitosan therefore undergoes reactions typical of amines: for example, 
N-acylation and Schiff reactions. 
 
Almost all functional properties of chitosan depend on the chain length, 
charge density, and charge distribution. 
 
Numerous studies have demonstrated that the salt form, molecular 
weight, and degree of deacetylation as well as pH at which the chitosan is used 
all influence how this polymer is utilized in pharmaceutical applications. 
 Acidity/alkalinity: pH = 4.0–6.0 (1 % w/v aqueous solution)  
 Density: 1.35–1.40 g cm-3  
 Glass transition temperature: 203 oC (Sakurai et al., 2000)  
 Moisture content: chitosan adsorbs moisture from the atmosphere, the 
amount of water adsorbed depending upon the initial moisture content 
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and the temperature and relative humidity of the surrounding air.  
 Particle size distribution: <30 mm  
 Solubility: sparingly soluble in water; practically insoluble in ethanol 
(95%), other organic solvents, and neutral or alkali solutions at pH 
above approximately 6.5. Chitosan dissolves readily in dilute and 
concentrated solutions of most organic acids and to some extent in 
mineral inorganic acids (except phosphoric and sulfuric acids). Upon 
dissolution, amine groups of the polymer become protonated, resulting 
in a positively charged polysaccharide (RNH3+) and chitosan salts 
(chloride, glutamate, etc.) that are soluble in water; the solubility is 
affected by the degree of deacetylation. Solubility is also greatly 
influenced by the addition of salt to the solution. The higher the ionic 
strength, the lower the solubility as a result of a salting-out effect, which 
leads to the precipitation of chitosan in solution when chitosan is in 
solution, the repulsions between the deactivated units and their 
neighbouring glucosamine units cause it to exist in an extended 
conformation. Addition of an electrolyte reduces this effect and the 
molecule possesses a more random, coil-like conformation.  
 Viscosity (dynamic): a wide range of viscosity types is commercially 
available. Owing to its high molecular weight and linear, unbranched 
structure, chitosan is an excellent viscosity enhancing agent in an acidic 
environment. It acts as a pseudo plastic material, exhibiting a decrease in 
viscosity with increasing rates of shear. The viscosity of chitosan solutions 
increases with increasing chitosan concentration, decreasing temperature, and 
increasing degree of deacetylation.  
 
Stability and Storage Conditions 
Chitosan powder is a stable material at room temperature, although it is 
hygroscopic after drying. Chitosan should be stored in a tightly closed container in a 
cool, dry place. The PhEur 2005 specifies that chitosan should be stored at a 
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temperature of 2–8 oC. 
 
Incompatibilities 
 
 Chitosan is incompatible with strong oxidizing agents.  
 
 
Safety 
Chitosan is being investigated widely for use as an excipient in oral and other 
pharmaceutical formulations. It is also used in cosmetics. Chitosan is generally 
regarded as a nontoxic and non-irritant material. It is biocompatible with both healthy 
and infected skin. Chitosan has been shown to be biodegradable. 
 LD50 (mouse, oral) >16 g kg-1  
Sodium Lauryl Sulphate 
Molecular Formula: C12H25NaO4S 
Average mass: 288.379 Da 
Monoisotopic mass: 288.137115 Da 
 
Fig  3. Structure of Sodium lauryl sulphate 
Application: 
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  Personal care products: 
   It is probably the most commonly used anionic surfactant in the personal-care 
business. 
  Shampoo, soap, bubble bath&detergents: Cleansing agent, surface-active 
agent, foaming agent. Creams, lotion and medical preparations: Emulsifying, 
foaming, wetting, dispersing agent.  Toothpaste: foaming, wetting, and dispersing 
agent. 
   Industrial applications: It's also used, in much higher concentrations, in industrial 
products such as car wash soap, engine degreasers, and floor cleaners. 
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4.AIM & OBJECTIVES 
 
 Formulated flavonoids exhibit ȕ-adrenergic receptor blocking activity and 
hence are practicing traditionally in various cardiovascular diseases like hypertension, 
angina pectoris, myocardial infarction and cardiac arrhythmias. Some of the ȕ-
blockers readily access the brain because of their lipophilicity thereby influencing 
some CNS functions. Propranolol is used for the treatment of anxiety syndromes, 
prophylaxis of migraine, schizophrenia and alcohol withdrawal syndrome and 
tremors. 
 
 From the literature survey, it can be understood that there are not many 
anxiolytic-anti-hypertensives in clinical use. Literature also indicates current therapy 
necessity of such a combined action drug that would lead to effective therapy at a 
lower cost devoid of related complications. 
  
 To explore the possibility of enhancement of both the activities without losing 
either.  
 To obtain a drugs with potentially more effective, safe, cheaper and more 
environmentally friendly alternatives to Formulated flavonoids. Based on the above 
reason, flavonoids are converted as a nanoparticles and evaluated by using anxiolytic  
animal models 
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5.PLAN OF WORK 
 Purchase the flavonoids. 
 Perform the confirmatory test for flavonoids. 
 Preformulation study 
 Formulation : Prepare the nanoparticles by nanoprecipitation method 
 Characterization of nanoparticles 
 Pharmacological studies 
               Invitro antioxidant studies 
                          Invivo studies:  
                                 1. Elevated plus maze 
                                 2. Light/ Dark Apparatus test 
                                 3. Open field apparatus test 
                                 4. Hole board apparatus 
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6.MATERIALS AND METHODS 
Materials  
 The flavonoid Berberine HCL has been procured from Sigma Aldrich, 
Chitosan from BASF Mumbai and Soudium lauryl sulphate from HD fine chemicals 
Mumbai and all other chemicals aand reagents are procured from reputed vendors 
having enough analytical grade and quality. 
 
Preformulation studies 
 FTIR spectra were recorded for all the physical mixtures of drug and the 
individual polymers in the ratio. Samples were prepared separately with potassium 
bromide (200- 400 mg) and compressed by applying the pressure of 200 kg/cm2 for 2 
min in hydraulic press to prepare the pellets. The samples were scanned in the range 
of 4000 to 400 cm-1 with resolution of 2 cm-1. 
Formulation (Solvent evaporation method) 
 Solvent evaporation techniques have become more useful method as compared 
to other methods. Controlled particle sizes in the nano to micrometer range can be 
achieved this method, but there is a need of careful selection of encapsulation 
materials and various conditions in order to achieve high. Encapsulation efficiency 
and a low residual solvent content. Several process variables had been identified by 
researchers which could affect the formulation of nanoparticles solvent evaporation 
method such as type of solvent, volume of solvent, drug to polymer ratio, rate of 
solvent removal, effect of internal aqueous phase volume in case of solvent 
evaporation followed by multiple emulsion, effect of addition of buffer or salts to the 
internal or external phase which can affect the size of nanoparticles and also the 
release pattern of the drug from microsphere. The need to optimize the release rate 
profile of drug from polymeric nanoparticles is a significant problem. So change in 
one of the above parameter causes the significant change in drugs loading & desired 
release rate. So our aim is to study the different process variables shown above to 
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optimize formulation, obtain high drug loading ability and to predict the release 
pattern. 
 
Fig 4. Solvent evaporation method 
 
Characterization of prepared nanoparticles: 
 Particle size analysis is performed by dynamic light scattering (DLS). 
Depending on the physical properties of the sample, the dynamic range is 0.3 nm – 8 
µm. The lower limit is influenced by concentration, how strongly the sample scatters 
light, and the presence of large, unwanted particles. The upper limit is influenced by 
the density of the sample since DLS is modelled on all motion coming from Brownian 
motion, not gravitational settling. Zeta potential is another important parameter that is 
related to nanoparticle stability or aggregation in a dispersion, and can have 
significant implications on product performance. 
 
 Animals:  
 Swiss albino mice weighing around 25 g – 30 g of either sex were obtained 
from Central animal house. Animals were maintained under standard laboratory 
conditions at an ambient temperature of 25°C. Animals had free access to food and 
water with a natural light and dark cycle. Animals were acclimatized for at least 5 
days before behavioral experiments. The study protocol was approved by Institutional 
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Animal Ethics Committee (IAEC) of the college and the experiments were carried out 
as per CPCSEA guidelines. 
 
Elevated plus maze 
 The Elevated plus maze (EPM) consisted of two open arms (25 x 5 cm) 
crossed with two closed arms (25 x 5 x 20 cm). The arms were connected together 
with a central square of 5 x 5 cm. The apparatus was elevated to a height of 25 cm. 
Mice in groups of 3 were treated with vehicle 0.5 % CMC diazepam (4mg/kg) and 
nanoparticles converted flavonoids 30 mg/kg. 30 min before placing the animals have 
individually in the center of plus maze. The time spent in open arms, entries in open 
and closed arms were recorded for a period of 5 min. 
 
Light/ Dark Apparatus test 
 Two equal sized boxes (20 x 20 x 14, one dark and the other lit) were 
connected with a tunnel (5 x 7 x 10 cm). Mice in groups of 3 treated with vehicle 0.5 
% CMC diazepam (4mg/kg) and nanoparticles converted flavonoids 30 mg/kg. 30 
min before were placed individually in the lit area. The number of transitions in the 
light and dark box and the time spent in the lit box were noted for 5 min. 
 
Open field apparatus test 
 The apparatus consisted of wooden box (96 x 96 x 25cm). The floor of the box 
was divided into 16 equal squares. Mice divided into groups of 3 treated with vehicle 
0.5 % CMC diazepam (4mg/kg) and nanoparticles converted flavonoids 30 mg/kg. 30 
min before were placed individually in the lit area. After 30 min they were placed 
individually in one comer of the square. The number of rearings and the number of 
squares traversed were counted for 5 min. 
 
Hole board apparatus 
 The apparatus consisted of wooden box (40x40x25cm) with 16 holes 
(diameter 3 cm) evenly distributed on the floor. The apparatus was elevated to a 
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height of 25 cm .Mice were treated with vehicle 0.5 % CMC, diazepam (4mg/kg) and 
nanoparticles converted flavonoids 30 mg/kg. 30 min before were placed individually 
in the lit area.) 30 min before placing in the apparatus and the number of head pokes 
during 5 min were recorded. 
INVITRO ANTIOXIDANT ACTIVITY 
The antioxidant activity tested using two methods: ferric thiocyanate (FTC) and 
thiobarbituric acid (TBA) methods. The FTC method was used to measure the amount 
of peroxide at the beginning of the lipid peroxidation, in which peroxide reacts with 
ferrous chloride and form ferric ion. The ferric ion then combines with ammonium 
thiocyanate and produce ferric thiocyanate. The substance is red in colour. The thicker 
the colour, the higher the absorbance. Whereas the TBA methods measures free 
radicals present after peroxide oxidation. 90 
 Ferric thiocyanate (FTC) method 
  The standard method as described by (Kikuzaki and Nakatani, 1993) was 
used1 . A mixture of 4.0 mg plant extract in 4ml absolute ethanol, 4.1 ml of 2.5% 
linolenic acid in absolute ethanol, 8.0 ml of 0.05M phosphate buffer (pH 7.0) and 3.9 
ml of water was placed in a vial with a screw cap and then placed in an oven at 40 ° C 
in the dark. To 0.1 ml of this solution was added 9.7 ml of 75% ethanol and 0.1 ml of 
30% ammonium thiocyanate. Precisely 3 min after addition of 0.1 ml of 0.02M 
ferrous chloride in 3.5% HCl to the reaction mixture, the absorbance of red colour 
was measured at 500nm each 24 hr until the day after absorbance of control reached 
maximum. BHT and α- tocopherol were used as positive controls while the mixture 
without plant sample was used as the negative control.  
Thiobarbituric acid (TBA) method  
 The method of (Ottolenghi, 1959)2 was referred. Two ml of 20% 
trichloroacetic acid and 2 ml of 0.67% 2-thiobarbituric acid was added to 1 ml of 
sample solution, as prepared in FTC method. The mixture was placed in a boiling 
water bath and, after cooling, was centrifuged at 3000 rpm for 20 min. Absorbance of 
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supernatant was measured at 552 nm. Antioxidant activity was based on the 
absorbance on the final day of FTC method.  
DPPH radical scavenging activity  
 The free radical scavenging activity by different plant extracts was done 
according to the method reported by (Gyamfi et al, 2002)3 . Fifty micro liters of the 
plant extract in methanol, yielding 100μg/ml respectively in each reaction was mixed 
with 1ml of 0.1mM DPPH in methanol solution and 450μl of 50mM Tris-HCl buffer 
(pH 7.4). Methanol (50μl) only was used as control of experiment. After 30 min of 
incubation at room temperature the reduction of the DPPH free radical was measured 
reading the absorbance at 517nm. L-Ascorbic acid and BHT used as controls. The 
percent inhibition was calculated from the following equation: % Inhibition = 
[Absorbance of control – Absorbance of test sample / Absorbance of control] × 100  
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7.RESULTS AND DISCUSSION 
Fourier transmission infrared spectroscopy:  
 FTIR spectra were recorded for all the physical mixtures of drug and the 
individual polymers in the ratio. Samples were prepared separately with potassium 
bromide (200- 400 mg) and compressed by applying the pressure of 200 kg/cm2 for 2 
min in hydraulic press to prepare the pellets. The samples were scanned in the range 
of 4000 to 400 cm-1 with resolution of 2 cm-1. 
 
 
Fig 5. FTIR of flavonoid (Berberine HCL), Chitosan and SLS) 
 The FTIR spectrum of the prepared complex shows that there is no significant 
change in the peak characteristics indicates that there is no interaction between either 
of the excipients. 
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Table 2.  Particle size, Zeta potential, PDI of Berberine nanoparticles 
Formulation Code Particle size Zeta potential (mV) PDI 
F1 206± 0.609 +41± 0.60 0.229± 0.76 
F2 207± 0.096 +45± 0.54 0.211± 0.45 
 
 
 
 
Fig 6. Scanning electron microscopy of formulation F1 
 
Fig 7. Scanning electron microscopy of formulation F2 
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Encapsulation efficiency and loading capacity of the nanoparticles 
 The encapsulation efficiency and loading capacity of F1 and F2 was found 
to be 84.6%,44.35% and 82.13%, 46.92% respectively.  The carboxyl group of 
berberine promotes electrostatic interaction with the amino group of chitosan and 
influence the encapsulation efficiency and loading capacity of nanoparticles. 
Table 3. Encapsulation Efficiency and Loading Capacity 
of the Nanoparticles 
Formulation code Encapsulation efficiency (%) Loading capacity (%) 
F1 81.4 47.88 
F2 83.45 43.64 
 
Table. 4: Elevated Plus Maze in Mice 
S. 
No 
Treatment  
mg / kg 
Entries 
O.A 
Entries 
C.A 
Spent 
O.A 
Head dips 
1 Control (0.5 % CMC) 2.55±0.55 5.55±1.7 31.77±6.23 6±2.30 
2 Diazepam 
4  
5.5±0.28 8.75±0.6 95.0 ± 9.64 13.0±1.22 
3 Nanoparticles 
converted flavonoids  
30 
3.5±0.28 6.75±1.2 75.0±1.64 11.0±1.14 
 
 The vehicle treated mice spent 31.77.8 ± 6.23 sec in the open arm and showed 
8± 0.86 entries in open arm, whereas animals treated  Nano particles converted 
 flavonoids (30 mg/kg) significantly (P<0.05) spent 75.0 ±1.64 sec in the open 
arm and also significantly (P<0.05) increased the entries in the open arms as 3.5 ± 
0.28, which are clarified in the Table. No: 1. 
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Table. 5. Open field in mice 
S. No Treatment  
mg / kg 
Squares traversed 
1 Control (0.5 % CMC) 75.8±14.54 
2 Diazepam 121.0±8.59 
3 Nanoparticles converted flavonoids  101.0±8.59 
 
 The vehicle treated mice traversed 75.6 ± 5.48 squares and reared 19.2 ± 2.67 times 
during the observation interval of 5 min and significantly (P<0.05) Nano particles 
converted flavonoids (30 mg/kg)  increased the number of squares traversed as 101.0 ± 
8.59, while dizepam 4 mg/kg  significantly  (P<0.05) 121.0±8.59 increased the rearings to 
40.6 ± 3.65. 
Table. 6. Number of head poking on hole board apparatus in mice 
S. No Treatment  
mg / kg 
Head dips 
(Secs) 
1 Control (0.5 % CMC) 24.2 ± 4.69 
2 Diazepam 44.8 ± 2.08 
3 Nanoparticles converted flavonoids  34.6 ± 6.59 
 
 The vehicle treated mice showed 24.2 ± 4.69 head dips. Diazepam 4 mg/kg  and  
Nano particles converted flavonoids 30 mg/kg) significantly (P<0.05) increased the 
number of head dips as 45 ± 1.14, 48.6 ±2.20 and 34.6 ± 6.59respectively (Table. No:3). 
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Table 7. Light/ Dark Apparatus test in mice 
S. No Treatment  
mg / kg 
Dark 
(Secs) 
Light 
(Secs) 
1 Control (0.5 % CMC) 124.2±4.69 138.2 ± 7.69 
2 Diazepam 
4  
244.8 ± 2.08 144.8 ± 2.08 
3 Nanoparticles converted flavonoids  
30 
234.6 ± 6.59 122.4 ± 7.08 
 
 The vehicle treated group spent 124.0 ± 4.69 sec in the dark surface of lit box 
and 138.2 ± 7.69  secs spent in light surface, whereas animals treated with Nano 
particles converted flavonoids (30 mg/kg) showed a significant (P<0.05) increase in 
the number of spent as 234.6 ± 6.59 secs when compared to each other groups, which 
are expressed in the form of Table. No:3. 
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8.SUMMARY AND CONCLUSION 
 The present investigation demonstrated that organization of the formulated 
nanao particles changes prompted action against anxiety. These discoveries affirmed 
depression like impacts of the flovonoid formulated nanoparticles through 
neurochemicals, homocysteine band neurocytokine components. Antiquated 
prescription is broadly held to advantageous yet for the most part neither the dynamic 
standards nor their atomic targets are all around characterized, along these lines, a 
comprehension of the dynamic segments and their components of activity can make 
such solutions more adequate. Flovonoid formulated nanoparticles is utilized as a 
restorative plant and its isolated compounds inferable from its various therapeutic 
properties. In Ayurveda, its leaves utilized for the change of memory, treatment of 
sensory system issue, mesmerizing, sedating and nearby analgesic exercises. It is 
having depressant, hostile to convulsive movement, change of memory and  through 
CNS activity. Because of contain of a few bioactive atoms like mannitol, glucose, 
fundamental oil, carotene, ȕ-amyrin, ȕ-sitosterol, hentriacontane, benzoic corrosive, 
triterpenoid (oleanolic corrosive, nyctanthic corrosive, friedeline, lupeol tannic 
corrosive, ascorbic corrosive, methyl salicylate, a formless glycoside and iridoid 
glycosides (arborsides A, B, C) but flavonoids have more anxiolytic properties.  
 
 Taking everything into account, our information demonstrated that low-
measurements of flovonoid formulated nanoparticles had an energizer action impact 
on constrain swim push incited melancholy model mice.  In future behavioral markers 
enhanced contrasted and model gathering. We found that 5HT, DA, GABA and NE 
level in serum and plasma, individually, were fundamentally expanded though MAO 
were diminish because of lesser restraint MAO. In this manner, we affirmed that 
flovonoid formulated nanoparticles has upper movement, its system might be 
flovonoid formulated nanoparticles stifled the level of plasma in focused on mice. 
Bringing down impact of flovonoid formulated nanoparticles may restart the re-
methylation and expanded the convergence of neurotransmitter. Still further human 
investigations are expected to demonstrate the wellbeing and viability of long haul 
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organization of flovonoid formulated nanoparticles takes off. In the light of 
perceptions made it might be visualized that pure falvonoids can be utilized as a 
potential adjuvant in the treatment of anxiety issue. 
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